An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016)
NCT02574260
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
3
Enrollment
INDUSTRY
Sponsor class
Conditions
Melanoma
Interventions
BIOLOGICAL:
Talimogene Laherparepvec
Sponsor
BioVex Limited
Collaborators
[object Object]